ProAxsis has developed a range of unique molecules, known as ProteaseTags ^®, which have the capacity to rapidly and selectively bind active proteases, including those which are biomarkers of diagnostic and prognostic value.

ProteaseTags ^® rapidly provide a visual readout of active proteases in complex biological samples with a high level of specificity and selectivity. In diseases characterised by abnormal protease action including but not limited to COPD, Bronchiectasis and Cystic Fibrosis. ProteaseTag ^® test systems have the potential to be incorporated into Point of Care tests, Companion Diagnostics, and activity-based immunoassays.